Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short.
Last Thursday in JAMA Oncology, Northwest Biotherapeutics and its scientific collaborators published the results of a large clinical trial showing its personalized cancer vaccine administered to patients with brain tumors reduced the risk of death by 20% compared to a group of patients taken from “external controls.” The same study results were presented Sunday at a neuro-oncology research meeting, as they were last May.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
